OBJECTIVES: Performance of the new Becton Dickinson ProbeTec GC Q(x) assay on the BD VIPER platform was evaluated to ascertain whether confirmatory testing is required in our clinical setting. METHODS: Positive predictive value (PPV) was determined by comparison with culture and a confirmatory nucleic acid amplification test (NAAT)-based Neisseria gonorrhoeae assay from genital and extragenital samples (rectal and pharyngeal) collected from a genitourinary medicine (GUM) clinic. RESULTS: Among 14,223 clinical genital samples, 149 (1.0%) specimens were positive using the ProbeTec GC Q(x) assay, automated on the VIPER platform; 141 of these were confirmed by either culture or a real-time PCR targeting two gonococcal-specific targets (PPV 94.6%; 95% CI 90% to 98%). Among 840 pharyngeal samples, 26 (3.1%) were positive by the ProbeTec GC Q(x) assay; 13 were confirmed (PPV 50%; 95% CI 30% to 70%). Among 593 rectal samples, 17 tested positive by the ProbeTec GC Q(x) assay; all were confirmed (PPV 100%; 95% CI 80% to 100%). CONCLUSIONS: The lower 95% CI of the PPV for the ProbeTec GC Q(x) assay for genital specimens was >90% in this GUM clinic population, and therefore confirmatory testing for genital specimens is not required. Confirmatory testing of pharyngeal and rectal samples should continue in line with national guidelines.
OBJECTIVES: Performance of the new Becton Dickinson ProbeTec GC Q(x) assay on the BD VIPER platform was evaluated to ascertain whether confirmatory testing is required in our clinical setting. METHODS: Positive predictive value (PPV) was determined by comparison with culture and a confirmatory nucleic acid amplification test (NAAT)-based Neisseria gonorrhoeae assay from genital and extragenital samples (rectal and pharyngeal) collected from a genitourinary medicine (GUM) clinic. RESULTS: Among 14,223 clinical genital samples, 149 (1.0%) specimens were positive using the ProbeTec GC Q(x) assay, automated on the VIPER platform; 141 of these were confirmed by either culture or a real-time PCR targeting two gonococcal-specific targets (PPV 94.6%; 95% CI 90% to 98%). Among 840 pharyngeal samples, 26 (3.1%) were positive by the ProbeTec GC Q(x) assay; 13 were confirmed (PPV 50%; 95% CI 30% to 70%). Among 593 rectal samples, 17 tested positive by the ProbeTec GC Q(x) assay; all were confirmed (PPV 100%; 95% CI 80% to 100%). CONCLUSIONS: The lower 95% CI of the PPV for the ProbeTec GC Q(x) assay for genital specimens was >90% in this GUM clinic population, and therefore confirmatory testing for genital specimens is not required. Confirmatory testing of pharyngeal and rectal samples should continue in line with national guidelines.
Authors: Sepehr N Tabrizi; Magnus Unemo; Athena E Limnios; Tiffany R Hogan; Stig-Ove Hjelmevoll; Susanne M Garland; John Tapsall Journal: J Clin Microbiol Date: 2011-08-03 Impact factor: 5.948
Authors: Sumudu R Perera; Nurul H Khan; Irene Martin; Ali Taheri; Rajinder P Parti; Paul N Levett; Greg B Horsman; Anthony Kusalik; Jo-Anne R Dillon Journal: J Clin Microbiol Date: 2017-08-16 Impact factor: 5.948
Authors: H S Tunsjø; E Smedsrud; P C Holm; K Rokvam; C Schie; V Rognlien; I Augustin; A Fostervold Journal: Eur J Clin Microbiol Infect Dis Date: 2013-08-01 Impact factor: 3.267
Authors: Marcus J Pond; Catherine L Hall; Victoria F Miari; Michelle Cole; Ken G Laing; Heena Jagatia; Emma Harding-Esch; Irene M Monahan; Timothy Planche; Jason Hinds; Catherine A Ison; Stephanie Chisholm; Philip D Butcher; Syed Tariq Sadiq Journal: J Antimicrob Chemother Date: 2016-01-26 Impact factor: 5.790
Authors: Sumudu R Perera; Ali Taheri; Nurul H Khan; Rajinder P Parti; Stephanie Stefura; Pauline Skiba; Jason P Acker; Irene Martin; Anthony Kusalik; Jo-Anne R Dillon Journal: Antibiotics (Basel) Date: 2018-08-04